QUANTIFY CANCER

Accurate MRD and response monitoring
is challenging and requires a novel approach to ctDNA detection and quantification.

Low levels of ctDNA in
early-stage cancer¹

ctDNA is challenging to detect in its earliest stages, requiring a highly sensitive approach to accurately detect and quantify cancer

Current assays only track
a small subset of variants²

Genomic-only information provides a narrow view of cancer, but a more comprehensive view is needed to understand cancer evolution

Background noise
impacts accuracy¹

Genomic-based approaches can be impacted by biological noise, including clonal hematopoiesis, that impacts accuracy of
ctDNA detection

Tissue-informed testing
has logistical challenges¹

Tissue-informed testing has several logistical challenges, including tissue insufficiency,
increased TAT due to procurement and processing, and invasive procedures

Next >

~40%

ctDNA, circulating tumor DNA; mNSCLC, metastatic non-small cell lung cancer;
MRD, minimal residual disease; TAT, turnaround time.

of first-line mNSCLC patients have insufficient tissue for comprehensive genomic profiling³

Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma